These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

83 related articles for article (PubMed ID: 24105953)

  • 21. Erythropoietic response to anemia in chronic hepatitis C patients receiving combination pegylated interferon/ribavirin.
    Balan V; Schwartz D; Wu GY; Muir AJ; Ghalib R; Jackson J; Keeffe EB; Rossaro L; Burnett A; Goon BL; Bowers PJ; Leitz GJ;
    Am J Gastroenterol; 2005 Feb; 100(2):299-307. PubMed ID: 15667486
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cost-efficacy analysis of peginterferon alfa-2b plus ribavirin compared with peginterferon alfa-2a plus ribavirin for the treatment of chronic hepatitis C.
    Malone DC; Tran TT; Poordad FF
    J Manag Care Pharm; 2005 Oct; 11(8):687-94. PubMed ID: 16194133
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Virologic response rates of weight-based taribavirin versus ribavirin in treatment-naive patients with genotype 1 chronic hepatitis C.
    Poordad F; Lawitz E; Shiffman ML; Hassanein T; Muir AJ; Bacon BR; Heise J; Halliman D; Chun E; Hammond J
    Hepatology; 2010 Oct; 52(4):1208-15. PubMed ID: 20721883
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Merimepodib, pegylated interferon, and ribavirin in genotype 1 chronic hepatitis C pegylated interferon and ribavirin nonresponders.
    Rustgi VK; Lee WM; Lawitz E; Gordon SC; Afdhal N; Poordad F; Bonkovsky HL; Bengtsson L; Chandorkar G; Harding M; McNair L; Aalyson M; Alam J; Kauffman R; Gharakhanian S; McHutchison JG;
    Hepatology; 2009 Dec; 50(6):1719-26. PubMed ID: 19852040
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Sustained virological response to pegylated interferon plus ribavirin leads to normalization of liver stiffness in hepatitis C virus-infected patients.
    Macías J; Rivero A; Cifuentes C; Camacho A; Neukam K; Rivero-Juárez A; Mira JA; Torre-Cisneros J; Gómez-Mateos J; Pineda JA
    Enferm Infecc Microbiol Clin; 2013; 31(7):424-9. PubMed ID: 23453582
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Synthesis and characterization of a hemoglobin-ribavirin conjugate for targeted drug delivery.
    Brookes S; Biessels P; Ng NF; Woods C; Bell DN; Adamson G
    Bioconjug Chem; 2006; 17(2):530-7. PubMed ID: 16536487
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Vitamin B12 diffusion and binding in crosslinked poly(acrylic acid)s and poly(acrylic acid-co-N-vinyl pyrrolidinone)s.
    Jin L; Lu P; You H; Chen Q; Dong J
    Int J Pharm; 2009 Apr; 371(1-2):82-8. PubMed ID: 19138732
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Design, synthesis and anti-hBV evaluation of adefovir mono-L-amino acid ester, mono non-steroidal anti-inflammatory drugs carboxylic ester prodrugs].
    Fu XZ; Wang YL; Lan YY; Wang AM; Ou Y; Luo C; Li Y
    Yao Xue Xue Bao; 2010 Aug; 45(8):1017-24. PubMed ID: 21351588
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Age and total ribavirin dose are independent predictors of relapse after interferon therapy in chronic hepatitis C revealed by data mining analysis.
    Kurosaki M; Hiramatsu N; Sakamoto M; Suzuki Y; Iwasaki M; Tamori A; Matsuura K; Kakinuma S; Sugauchi F; Sakamoto N; Nakagawa M; Yatsuhashi H; Izumi N
    Antivir Ther; 2012; 17(1):35-43. PubMed ID: 22267467
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Poly(vinyl alcohol) physical hydrogel nanoparticles, not polymer solutions, exert inhibition of nitric oxide synthesis in cultured macrophages.
    Andreasen SØ; Chong SF; Wohl BM; Goldie KN; Zelikin AN
    Biomacromolecules; 2013 May; 14(5):1687-95. PubMed ID: 23560438
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Early monitoring of ribavirin serum concentration is not useful to optimize hepatitis C virus treatment in HIV-coinfected patients.
    Crespo M; Pou L; Esteban JI; Falcó V; Ribera E; Lopez R; Sauleda S; Curran A; Villar del Saz S; Feijoo M; Ocaña I; Pahissa A
    Antivir Ther; 2007; 12(8):1217-23. PubMed ID: 18240861
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Tumor cell-specific prodrugs using arsonic acid-presenting iron oxide nanoparticles with high sensitivity.
    Minehara H; Narita A; Naka K; Tanaka K; Chujo M; Nagao M; Chujo Y
    Bioorg Med Chem; 2012 Aug; 20(15):4675-9. PubMed ID: 22743089
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pegylated interferon alpha-2b plus ribavirin in the treatment of post-liver transplant recurrent hepatitis C.
    Ross AS; Bhan AK; Pascual M; Thiim M; Benedict Cosimi A; Chung RT
    Clin Transplant; 2004 Apr; 18(2):166-73. PubMed ID: 15016131
    [TBL] [Abstract][Full Text] [Related]  

  • 34. ITPA genotype protects against anemia during peginterferon and ribavirin therapy but does not influence virological response.
    Holmes JA; Roberts SK; Ali RJ; Dore GJ; Sievert W; McCaughan GW; Crawford DH; Cheng WS; Weltman MD; Bonanzinga S; Visvanathan K; Sundararajan V; Desmond PV; Bowden DS; Matthews GV; Thompson AJ;
    Hepatology; 2014 Jun; 59(6):2152-60. PubMed ID: 24449403
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Triple therapy with first generation HCV protease inhibitors: lead-in or no lead-in phase?
    Pascale A; Serfaty L
    J Hepatol; 2013 Feb; 58(2):391-4. PubMed ID: 23063419
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Lower Ribavirin Plasma Concentrations in HCV/HIV-Coinfected Patients Than in HCV-Monoinfected Patients Despite Similar Dosage.
    Deenen MJ; de Kanter CT; Dofferhoff AS; Grintjes-Huisman KJ; van der Ven AJ; Fleuren HW; Gisolf EH; Koopmans PP; Drenth JP; Burger DM
    Ther Drug Monit; 2015 Dec; 37(6):751-5. PubMed ID: 26102531
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Epoetin alfa treatment for acute anaemia during interferon plus ribavirin combination therapy for chronic hepatitis C.
    Bräu N
    J Viral Hepat; 2004 May; 11(3):191-7. PubMed ID: 15117320
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Multifunctional polyvinylpyrrolidinone-polyacrylic acid copolymer hydrogels for biomedical applications.
    Devine DM; Devery SM; Lyons JG; Geever LM; Kennedy JE; Higginbotham CL
    Int J Pharm; 2006 Dec; 326(1-2):50-9. PubMed ID: 16926073
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Minimal impact of sofosbuvir and ribavirin on health related quality of life in chronic hepatitis C (CH-C).
    Younossi ZM; Stepanova M; Henry L; Gane E; Jacobson IM; Lawitz E; Nelson D; Nader F; Hunt S
    J Hepatol; 2014 Apr; 60(4):741-7. PubMed ID: 24333184
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Association between the influential factors and the effectiveness of pegylated interferon alpha-2a plus ribavirin as a combination treatment for chronic hepatitis C patients].
    He LL; Chen Z; Chen Y; Xu H; Tang H; Lei BJ; Lei XZ
    Zhonghua Gan Zang Bing Za Zhi; 2011 Jan; 19(1):34-7. PubMed ID: 21272456
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.